Scarica l'app Stockscreener
233.42
4.24%
9.49
Pre-mercato:
230.48
-2.94
-1.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$223.93
Aprire:
$225.24
Volume 24 ore:
9.79M
Relative Volume:
1.73
Capitalizzazione di mercato:
$412.54B
Reddito:
$59.64B
Utile/perdita netta:
$2.36B
Rapporto P/E:
176.13
EPS:
1.3253
Flusso di cassa netto:
$19.68B
1 W Prestazione:
+2.16%
1M Prestazione:
+3.25%
6M Prestazione:
+24.40%
1 anno Prestazione:
+30.02%
Intervallo 1D:
$224.74
$237.04
Intervallo di 1 settimana:
$217.86
$237.04
Portata 52W:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down - TechStock²
Revolution Medicines dips after AbbVie denies takeover talks - TradingView — Track All Markets
AbbVie (ABBV) Stock Drops as Company Denies Revolution Medicines Acquisition Reports - CoinCentral
AbbVie Lowers Q4, 2025 Adjusted EPS Guidance - MarketScreener
Why Revolution Medicines Shares Are Sliding After Hours On Wednesday - Benzinga
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
AbbVie (ABBV) Projects Q4 Earnings Impact from $1.3 Billion Char - GuruFocus
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie flags $1.3B IPR&D charge, warns of Q4 earnings pressure (ABBV:NYSE) - Seeking Alpha
Revolution Medicines Stock Pre-Market (-6.0%): AbbVie Denies Acquisition Talks - Trefis
AbbVie Denies Media Reports of Talks to Buy Revolution Medicines - MarketScreener
AbbVie denies media reports of talks to buy Revolution Medicines - WTVB
Exclusive | Revolution Medicines Draws Takeover InterestWSJ - The Wall Street Journal
Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks - Stocktwits
Stock Movers: Jeffries, AbbVie, Raytheon - Bloomberg.com
AbbVie2025 adjusted EPS guidance range $9.90$9.94SEC filing - MarketScreener
Revolution Medicines (RVMD) Shares Plunge After AbbVie Denies Acquisition Talks - GuruFocus
Abbvie denies WSJ report of talks to buy biotech player Revolutions Medicine - Crain's Chicago Business
AbbVie (ABBV) Denies Acquisition Talks with Revolution Medicines - GuruFocus
AbbVie (ABBV) Denies Discussions with Revolution Medicines - GuruFocus
AbbVie Says It’s Not in Talks to Buy Revolution Medicines - Bloomberg.com
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
AbbVie reports $1.3 billion Q4 expense from acquired research deals - StreetInsider
Revolution Medicines (RVMD) Surges on AbbVie Acquisition Talks - GuruFocus
AbbVie (ABBV) Nears Acquisition Deal with Revolution Medicines - GuruFocus
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
AbbVie M&A Buzz Sends Revolution Medicines RVMD Above $100, ABBV Stock $230+ - FXLeaders
AbbVie (ABBV) Nears Acquisition of Cancer-Drug Firm Revolution M - GuruFocus
AbbVie (ABBV) Reportedly Nears Acquisition of Revolution Medicines - GuruFocus
American pharmaceutical giant in advanced negotiations for a major acquisition - medwatch.com
Exclusive | AbbVie Near Deal for Revolution MedicinesWSJ - The Wall Street Journal
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition - MarketScreener
AbbVie in talks to buy biotech Revolution Medicines, WSJ reports - TradingView — Track All Markets
AbbVie in Advanced Talks to Acquire Revolution Medicines - MarketScreener
Revolution Medicines stock surges over 20% on potential AbbVie acquisition By Investing.com - Investing.com UK
AbbVie Close to Deal for Cancer Drugmaker RevMed, WSJ Says - Bloomberg.com
AbbVie, Revolution Medicines said to be close to deal - breakingthenews.net
AbbVie in Advanced Discussions to Acquire Revolution Medicines, WSJ Reports - MarketScreener
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - Yahoo Finance
UBS Raises AbbVie (ABBV) Price Target to $240 While Maintaining Neutral Rating | ABBV Stock News - GuruFocus
UBS assumes coverage of Abbvie stock with Neutral rating, $240 price target - Investing.com Canada
AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next - TechStock²
New year sees Abbvie, Zelgen in $1.1B T-cell engager deal - BioWorld MedTech
What Can Trigger A Breakout In Abbvie Stock? - Forbes
OneAscent Financial Services LLC Reduces Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Spirepoint Private Client LLC - MarketBeat
Greenleaf Trust Sells 28,666 Shares of AbbVie Inc. $ABBV - MarketBeat
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
AbbVie Inc. $ABBV Holdings Lifted by Torray Investment Partners LLC - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Sitrin Capital Management LLC - MarketBeat
What Could Spark the Next Big Move In AbbVie Stock - Trefis
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.32%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):